Stock Market & Financial Investment News

News Breaks September 14, 2012 06:17 EDT DGX Quest Diagnostics removed from U.S. Focus List at Credit Suisse Note that shares were downgraded by Credit Suisse this morning. News For DGX From The Last 14 Days Check below for free stories on DGX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 13, 2013 17:23 EDT DGX Quest Diagnostics to offer cancer tests, DJ reports Subscribe for More Information 16:25 EDT DGX On The Fly: Closing Wrap Subscribe for More Information 15:29 EDT DGX Quest Diagnostics to offer BRCA1 and BRCA2 cancer tests late 2013, DJ reports Subscribe for More Information June 6, 2013 16:07 EDT DGX Quest Diagnostics sees 2H13 results improving vs. prior year Subscribe for More Information 16:04 EDT DGX Quest Diagnostics sees Q2 results up sequentially, sees Q2 results down YoY 16:03 EDT DGX Quest Diagnostics reaffirms FY13 EPS view $4.35 and $4.55, consensus $4.35 Sees revenues to approximate the prior-year level , consensus $7.31B. 15:11 EDT DGX QIAGEN affirms FY13 view after Quest Diagnostics, Hologic strike deal QIAGEN (QGEN) said its full-year earnings view will not be changed following an announcement that Quest Diagnostics (DGX) and Hologic (HOLX) reached a supply agreement. WHAT'S NEW: Earlier today, Quest Diagnostics and Hologic announced a non-exclusive agreement for Quest to more broadly offer Hologic's APTIMA family of testing products. Hologic's APTIMA line includes FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas vaginalis. WHAT'S NOTABLE: Following the announcement, QIAGEN, which competes with Hologic in the diagnostic product space, said that a "U.S. reference laboratory customer" of its products made public a deal to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN said the customer would continue to offer its HPV-related products as well. QIAGEN said that it saw no need to revise its full-year 2013 guidance based on the development. The company also noted that sales related to this development represent less than 2% of the company's anticipated 2014 sales, and HPV screening in the U.S. is expected to represent less than 10% of the company's 2014 total net sales. PRICE ACTION: Hologic advanced following news of its agreement with Quest, and its shares are up over 2% in afternoon trade. QIAGEN shares are off their best levels, but still higher by about 0.5%. 13:08 EDT DGX Quest Diagnostics, Hologic in strategic alliance for women's health Subscribe for More Information 09:44 EDT DGX Quest Diagnostics has a conference call hosted by JPMorgan Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.